Arch Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ARTH research report →
Companywww.archtherapeutics.com
Arch Therapeutics, Inc. , together with its subsidiaries, operates as a biotechnology company in the United States. The company develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease.
- CEO
- Terrence W. Norchi
- IPO
- 2013
- Employees
- 8
- HQ
- Framingham, MA, US
Price Chart
Valuation
- Market Cap
- $444
- P/E
- -0.00
- P/S
- 0.01
- P/B
- -0.00
- EV/EBITDA
- -1.39
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -3.22%
- Op Margin
- -6661.67%
- Net Margin
- -9221.43%
- ROE
- 119.36%
- ROIC
- 268.33%
Growth & Income
- Revenue
- $75.72K · 383.80%
- Net Income
- $-6,982,836 · -63.31%
- EPS
- $-2.27 · 36.24%
- Op Income
- $-5,044,483
- FCF YoY
- 24.18%
Performance & Tape
- 52W High
- $1.57
- 52W Low
- $0.00
- 50D MA
- $0.18
- 200D MA
- $0.32
- Beta
- 4.03
- Avg Volume
- 2.12K
Get TickerSpark's AI analysis on ARTH
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 31, 23 | ABRAMS MICHAEL S | other | 20,584 |
| Aug 31, 23 | ABRAMS MICHAEL S | buy | 10,292 |
| Aug 31, 23 | Norchi Terrence W | other | 13,724 |
| Aug 31, 23 | Norchi Terrence W | buy | 6,862 |
| Aug 31, 23 | Hicks Laurence | other | 20,584 |
| Aug 31, 23 | Hicks Laurence | buy | 10,292 |
| Nov 10, 22 | DHILLON PUNIT | other | 250,000 |
| Nov 10, 22 | Fish Guy L. | other | 250,000 |
| Nov 10, 22 | Hicks Laurence | other | 250,000 |
| Nov 10, 22 | Yrigoyen Dan | other | 500,000 |
Our ARTH Coverage
We haven't published any research on ARTH yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ARTH Report →